Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Swetha Kambhampati; Monica Saumoy; Yecheskel Schneider; Stacy Pak; Lihua Elizabeth Budde; Matthew G. Mei; Tanya Siddiqi; Leslie L. Popplewell; Yi Ping Wen; Jasmine Zain; Stephen J. Forman; Larry W. Kwak; Steven T. Rosen; Alexey V. Danilov; Alex F. Herrera; Nikhil R. Thiruvengadam

doi:10.1182/blood.2022016624

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Swetha Kambhampati
, Monica Saumoy
, Yecheskel Schneider
, Stacy Pak
, Lihua Elizabeth Budde
, Matthew G. Mei
, Tanya Siddiqi
, Leslie L. Popplewell
, Yi Ping Wen
, Jasmine Zain
, Stephen J. Forman
, Larry W. Kwak
, Steven T. Rosen
, Alexey V. Danilov
, Alex F. Herrera
, Nikhil R. Thiruvengadam

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2697-2708
Number of pages	12
Journal	Blood
Volume	140
Issue number	25
DOIs	https://doi.org/10.1182/blood.2022016624
State	Published - Dec 22 2022

ASJC Scopus Subject Areas

Biochemistry
Immunology
Hematology
Cell Biology

Keywords

Prednisone/therapeutic use
Doxorubicin/adverse effects
Lymphoma, Large B-Cell, Diffuse/drug therapy
Humans
Cost-Benefit Analysis
Adult
Aged
Rituximab/therapeutic use
Vincristine/adverse effects
Cyclophosphamide/adverse effects
Antineoplastic Combined Chemotherapy Protocols/adverse effects

Access to Document

10.1182/blood.2022016624

OpenUrl availability

Full text

Cite this

Kambhampati, S., Saumoy, M., Schneider, Y., Pak, S., Budde, L. E., Mei, M. G., Siddiqi, T., Popplewell, L. L., Wen, Y. P., Zain, J., Forman, S. J., Kwak, L. W., Rosen, S. T., Danilov, A. V., Herrera, A. F., & Thiruvengadam, N. R. (2022). Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood, 140(25), 2697-2708. https://doi.org/10.1182/blood.2022016624

Kambhampati, S, Saumoy, M, Schneider, Y, Pak, S, Budde, LE, Mei, MG, Siddiqi, T, Popplewell, LL, Wen, YP, Zain, J, Forman, SJ, Kwak, LW, Rosen, ST, Danilov, AV, Herrera, AF & Thiruvengadam, NR 2022, 'Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma', Blood, vol. 140, no. 25, pp. 2697-2708. https://doi.org/10.1182/blood.2022016624

@article{b776f4179e04499ba1b3508a443d856e,

title = "Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma",

keywords = "Prednisone/therapeutic use, Doxorubicin/adverse effects, Lymphoma, Large B-Cell, Diffuse/drug therapy, Humans, Cost-Benefit Analysis, Adult, Aged, Rituximab/therapeutic use, Vincristine/adverse effects, Cyclophosphamide/adverse effects, Antineoplastic Combined Chemotherapy Protocols/adverse effects",

author = "Swetha Kambhampati and Monica Saumoy and Yecheskel Schneider and Stacy Pak and Budde, \{Lihua Elizabeth\} and Mei, \{Matthew G.\} and Tanya Siddiqi and Popplewell, \{Leslie L.\} and Wen, \{Yi Ping\} and Jasmine Zain and Forman, \{Stephen J.\} and Kwak, \{Larry W.\} and Rosen, \{Steven T.\} and Danilov, \{Alexey V.\} and Herrera, \{Alex F.\} and Thiruvengadam, \{Nikhil R.\}",

note = "Publisher Copyright: {\textcopyright} 2022 The American Society of Hematology",

year = "2022",

month = dec,

day = "22",

doi = "10.1182/blood.2022016624",

language = "English",

volume = "140",

pages = "2697--2708",

journal = "Blood",

issn = "0006-4971",

number = "25",

}

TY - JOUR

T1 - Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

AU - Kambhampati, Swetha

AU - Saumoy, Monica

AU - Schneider, Yecheskel

AU - Pak, Stacy

AU - Budde, Lihua Elizabeth

AU - Mei, Matthew G.

AU - Siddiqi, Tanya

AU - Popplewell, Leslie L.

AU - Wen, Yi Ping

AU - Zain, Jasmine

AU - Forman, Stephen J.

AU - Kwak, Larry W.

AU - Rosen, Steven T.

AU - Danilov, Alexey V.

AU - Herrera, Alex F.

AU - Thiruvengadam, Nikhil R.

PY - 2022/12/22

Y1 - 2022/12/22

KW - Prednisone/therapeutic use

KW - Doxorubicin/adverse effects

KW - Lymphoma, Large B-Cell, Diffuse/drug therapy

KW - Humans

KW - Cost-Benefit Analysis

KW - Adult

KW - Aged

KW - Rituximab/therapeutic use

KW - Vincristine/adverse effects

KW - Cyclophosphamide/adverse effects

KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects

UR - https://www.scopus.com/pages/publications/85141931473

UR - https://www.scopus.com/pages/publications/85141931473#tab=citedBy

UR - https://www.mendeley.com/catalogue/6c494cda-7180-3a16-890b-19b6b888bc4c/

U2 - 10.1182/blood.2022016624

DO - 10.1182/blood.2022016624

M3 - Article

C2 - 35700381

AN - SCOPUS:85141931473

SN - 0006-4971

VL - 140

SP - 2697

EP - 2708

JO - Blood

JF - Blood

IS - 25

ER -

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

ASJC Scopus Subject Areas

Keywords

Access to Document

OpenUrl availability

Other files and links

Cite this